Progress, Potential, and Possibilities Podcast / Show The Future of Psychedelic Medicine | Interview with Compass Pathways CEO Kabir Nath
Kabir Nath is Chief Executive Officer of Compass Pathways ( https://compasspathways.com/ ), a biotechnology company pioneering evidence-based psychedelic innovation for serious mental health conditions.
Kabir brings nearly three decades of leadership experience across the biopharmaceutical and medical device industries. Before joining Compass, he served as Senior Managing Director of Global Pharmaceuticals at Otsuka Pharmaceutical Co., and previously as President and CEO of Otsuka’s North America Pharmaceutical Business, where he led the development of therapies and digital solutions addressing complex mental health needs. Earlier in his career, he held senior leadership roles at Bristol Myers Squibb.
Under Kabir’s leadership, Compass has advanced COMP360 — a synthetic, proprietary formulation of psilocybin — through two pivotal Phase 3 trials in treatment-resistant depression. The program has demonstrated statistically significant and clinically meaningful reductions in depression severity, potentially positioning COMP360 to become the first FDA-approved psilocybin-based treatment.
Kabir holds an MA from the University of Cambridge and an MBA from INSEAD.
#PsychedelicMedicine #Psilocybin #DepressionTreatment #MentalHealthInnovation #CompassPathways #COMP360 #TreatmentResistantDepression #Biotech #Neuroscience #FutureOfPsychiatry #ClinicalTrials #MentalHealthResearch #PsychedelicTherapy #BiotechInterview #DrugDevelopment